DBVT

DBV Technologies S.A.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1613780Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$6.0M

Net Income FY2025

$(147.0M)

EPS (Basic, as reported)

$-1.05

Net Margin FY2025

-2607.3%

ROE FY2025

-87.1%

Total Equity

$169.0M

Shares Out

296M

Business description

DBV Technologies S.A. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 15 → 6 -14.2% CAGR

Fiscal yearFY2019FY2020FY2021⚑FY2022FY2023FY2024⚑FY2025

Revenue1511651646

Research & development(115)(102)(70)(76)(60)(89)(117)

Selling & marketing(22)(10)(4)(2)(2)(3)(3)

General & administrative(49)(35)(31)(24)(29)(29)(33)

Total operating expenses(186)(170)(104)(101)(92)(121)(153)

Operating income(171)(159)(99)(97)(76)(117)(147)

Pre-tax income(171)(160)(98)(96)(73)(114)(146)

Income tax expense(1)000000

Net income(172)(160)(98)(96)(73)(114)(147)

EPS — basic——($1.78)($1.24)($0.76)($1.17)($1.05)

EPS — diluted——($1.78)($1.24)($0.76)($1.17)($1.05)

Shares outstanding — basic (M)——55779597140

Shares outstanding — diluted (M)——55779597140

⚑ Weighted-average shares changed ×1.40 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.44 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.